We are live on !
Find out more
Boxer Capital Portfolio holdings
AUM
$2.04B
Turnover
20.83%
1-Year Est. Return
108.39%
This Fund
S&P 500
This Quarter Est. Return
+54.07%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.1%
10 Year Est. Return
–
AUM
$223M
AUM Growth
+$110M
(+98%)
Cap. Flow
+$42.4M
Cap. Flow % of AUM
Cap. Flow %
18.99%
Top 10 Holdings %
Top 10 Hldgs %
78.3%
Holding
30
New
7
Increased
5
Reduced
4
Closed
2
Avg Time Held
Equity + Options
0.4
years
Top 10 Avg Time Held
Equity + Options
0.4
years
Top 20 Avg Time Held
Equity + Options
0.4
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDCO
Medicines Co
MDCO
|
+$26.4M |
| 2 |
CLVS
Clovis Oncology
CLVS
|
+$11.8M |
| 3 |
AVXS
AveXis
AVXS
|
+$5.97M |
| 4 |
Heron Therapeutics
HRTX
|
+$3.71M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$2.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$6.98M |
| 2 |
Acadia Healthcare
ACHC
|
+$6.52M |
| 3 |
TSRO
Tesaro
TSRO
|
+$3.74M |
| 4 |
Carisma Therapeutics
CARM
|
+$931K |
| 5 |
ARDM
Aradigm
ARDM
|
+$832K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.73% |
| 2 | Miscellaneous | 12.27% |
Similar funds
Boxer Capital's Q3 2016 Portfolio in Review
As of Q3 2016, Boxer Capital held 30 positions worth $223M, up 98% from $113M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Boxer Capital deployed $42.4M of net new capital in Q3 2016, opening 7 new positions and adding to 5 existing holdings. Its largest new stake was Medicines Co: 700,000 shares worth $26.4M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Tesaro, an estimated $3.74M trimmed.
- Boxer Capital's largest Q3 2016 buy was Medicines Co: 700,000 shares worth $26.4M.
- Boxer Capital added most to Clovis Oncology in Q3 2016, an estimated $11.8M increase.
- Boxer Capital's biggest Q3 2016 reduction was Tesaro, cutting an estimated $3.74M.
- Boxer Capital fully exited Regeneron Pharmaceuticals in Q3 2016, selling an estimated $6.98M.
- Boxer Capital's ten largest holdings make up 78% of its $223M portfolio in Q3 2016.
- Boxer Capital opened 7 new positions and closed 2 in Q3 2016.
- Boxer Capital's portfolio value rose 98% quarter-over-quarter to $223M.
Based on Boxer Capital's 13F filing for Q3 2016, filed 14 Nov 2016.